Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tuvusertib in Combination With Niraparib or Lartesertib in Ovarian Cancer
NCT06433219Phase 2Completed
- Sponsor
- EMD Serono
- Start
- Oct 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of tuvusertib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (5 arms), sponsored by EMD Serono. Primary endpoints: Confirmed Objective Response up to 3.5 years and Number of Participants With Treatment-Emergent Adverse Events up to 3.5 years. Started Oct 2024; status: completed.
02
Drugs
tuvusertib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06433219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433219.